Key Points
- Moderna President Stephen Hoge sold 40,294 shares for approximately $5.8 million at an average price of $144.13, reducing his ownership by 2.57% to 1.53 million shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Moderna shares opened at $145.62, while the company reported quarterly revenue of $145 million and an adjusted loss of $1.97 per share, modestly exceeding analyst expectations.
- Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $76.72, despite optimism surrounding Moderna’s personalized cancer-vaccine pipeline and Merck collaboration.
Moderna, Inc. (NASDAQ:MRNA - Get Free Report) President Stephen Hoge sold 40,294 shares of the company's stock in a transaction on Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the completion of the sale, the president owned 1,525,858 shares in the company, valued at $219,921,913.54. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Stephen Hoge also recently made the following trade(s):
- On Tuesday, September 15th, Stephen Hoge sold 40,281 shares of Moderna stock. The stock was sold at an average price of $146.07, for a total transaction of $5,883,845.67.
Moderna Trading Up 1.3%
Shares of MRNA stock opened at $145.62 on Thursday. The company has a market capitalization of $58.14 billion, a P/E ratio of -18.23 and a beta of 1.10. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $176.66. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average price of $96.37 and a 200 day moving average price of $68.84.
Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. During the same quarter last year, the business posted ($2.13) earnings per share. The company's revenue was up 2.1% on a year-over-year basis. Research analysts forecast that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Moderna
Hedge funds and other institutional investors have recently made changes to their positions in the company. Allied Private Wealth LLC acquired a new stake in Moderna in the second quarter worth about $30,000. Canton Hathaway LLC acquired a new position in Moderna during the 1st quarter valued at about $31,000. Archer Investment Corp bought a new position in shares of Moderna in the 2nd quarter valued at about $36,000. Assetmark Inc. boosted its stake in shares of Moderna by 35.1% in the 1st quarter. Assetmark Inc. now owns 801 shares of the company's stock valued at $41,000 after purchasing an additional 208 shares during the last quarter. Finally, Frazier Financial Advisors LLC acquired a new stake in shares of Moderna during the 2nd quarter worth approximately $45,000. 75.33% of the stock is owned by institutional investors and hedge funds.
More Moderna News
Here are the key news stories impacting Moderna this week:
- Positive Sentiment: Investor optimism is building around Moderna’s personalized cancer-vaccine program and its collaboration with Merck. Analysts see oncology as a potential long-term growth engine that could help offset weaker COVID-19 vaccine revenue and support a broader business turnaround. Speculation that Merck could acquire Moderna adds to the strategic appeal, although no transaction has been announced. Why Merck Should Buy Moderna
- Positive Sentiment: Recent coverage highlights Moderna’s strong stock recovery and investors’ growing willingness to value the company on its pipeline rather than solely on COVID-19 products. Moderna’s latest quarterly revenue also exceeded expectations, providing some support for the recovery narrative. Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
- Neutral Sentiment: Institutional ownership remains substantial, with major investors including BlackRock and California State Teachers’ Retirement System reporting sizable positions. This may improve trading support, but the cited holdings largely reflect earlier reporting periods rather than a new catalyst.
- Neutral Sentiment: Analyst opinion remains mixed: Moderna has Buy, Hold and Sell ratings, with a consensus Hold rating. This suggests investors recognize the pipeline opportunity but remain cautious about valuation, execution and the company’s path back to profitability.
- Negative Sentiment: President Stephen Hoge sold a combined 80,575 shares worth approximately $11.7 million over September 14–15. CFO James Mock also sold 34,836 shares, reducing his direct holdings by about 37%. All reported transactions were made under pre-arranged Rule 10b5-1 plans, limiting their value as discretionary bearish signals, but the insider selling could still weigh on sentiment. Moderna SEC insider-trading filing
Wall Street Analyst Weigh In
MRNA has been the topic of several research analyst reports. The Goldman Sachs Group increased their target price on Moderna from $67.00 to $120.00 and gave the stock a "neutral" rating in a report on Wednesday, August 19th. Citigroup lifted their price target on Moderna from $41.00 to $60.00 and gave the company a "neutral" rating in a report on Monday, August 3rd. JPMorgan Chase & Co. upped their price target on shares of Moderna from $40.00 to $77.00 and gave the stock an "underweight" rating in a research report on Friday, August 21st. CLSA raised shares of Moderna to an "outperform" rating in a report on Friday, August 28th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Moderna in a research report on Wednesday, September 9th. Seven research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have given a Sell rating to the company's stock. Based on data from MarketBeat, Moderna currently has a consensus rating of "Hold" and an average target price of $76.72.
Get Our Latest Stock Analysis on Moderna
Moderna Company Profile
(
Get Free Report)
Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.
The company's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.
Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
